Orphan Drugs in Surgery

Open access

Summary

Introduction. Rare diseases, also called orphan diseases, are life-threatening or chronically debilitating conditions of different origin. Majority of them are genetic disorders, others being rare cancers, congenital malformations, autoimmune, toxic and infectious diseases. Rare conditions may also be related to surgery, e.g. acute sensorineural hearing loss after surgery induced acoustic trauma, scarring post glaucoma filtration surgery, and short bowel syndrome following intestinal surgery. Besides, surgery as a specific area for orphan drugs, has not been studied yet in Latvia.

Aim of the study. This study aims to determine orphan drugs associated with surgery (used pre-, during or post-surgery) and their availability and access in Latvia.

Materials and methods. European register of designated orphan medicinal products and EMA approved Summary of Product Characteristics were analyzed, to find orphan drugs with approved labeled indications related to surgery. Drug availability and access in Latvia were determined, by using data available from State Agency of Medicines of Latvia and National Health Service. A literature review was performed to compare Latvian situation in field of orphan medicines with other European countries.

Results. 15 orphan drugs were identified, 8 of them (53.3%) indicated for different kinds of tumors. 6 drugs (40%) are available in Latvia, including one drug (6.7%) included in the reimbursement list.

Conclusions. Oncology is the biggest therapeutic area of orphan drugs. Majority of orphan drugs are not available in Latvia, moreover those drugs that are available are often not accessible.

References
  • 1. Bignami F. Eurordis survey on orphan drugs availability in Europe // 6th Eurordis Round Table of Companies Workshop, Barcelona, Spain, 2007 (http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf, accessed 05.04.2013.)

  • 2. Boon W, Moors E. Exploring emerging technologies using metaphors-a study of orphan drugs and pharmacogenomics // Soc Sci Med, 2008; 66:1915-1927

  • 3. Cito! // Newsletter of State Agency of Medicines of Latvia (Zāļu valsts aģentūras informatīvs izdevums), 2012; 1(48):7-9 (http://www.zva.gov.lv/doc_upl/ cito-nr48-web.pdf, accessed 05.04.2013.)

  • 4. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe’s challenges // Commission of the European Communities, Brussels, 2008 (http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf, accessed 05.04.2013.)

  • 5. Council Recommendation of 8 June 2009 on an action in the field of rare diseases // Official Journal of the European Communities, 2009; C151:7-10 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF, accessed 05.04.2013.)

  • 6. de Varax A, Letellier M, Börtlein G. Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe // Alcimed, Paris, France, 2004 (http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_wwe_en.pdf, accessed 05.04.2013.)

  • 7. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets // Health Policy, 2010; 97:173-179

  • 8. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013 // J Med Econ, 2010; 13(2):295-301

  • 9. Drug Register of the Republic of Latvia, 2013 (Latvijas Republikas Zāļu reģistrs 2013) // State Agency of Medicines of Latvia, Riga, 2013 (Rīga. Zāļu valsts aģentūra, 2013) (http://www.zva. gov.lv/?id=375&sa=375&top=334, accessed 05.04.2013.)

  • 10. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs // Int J Technol Assess Health Care, 2007; 23(1):36-42

  • 11. Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria // Health Policy, 2012; 108:10-18

  • 12. Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis // Eurordis, Paris, France, 2010 (http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC_13122010_ YLeCam_Final.pdf, accessed 05.04.2013.)

  • 13. List of rare disease designations // European Medicines Agency (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_searse.jsp&mid=WC0b01ac058001d12b, accessed 05.04.2013.)

  • 14. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues // Expert Rev Pharmacoecon Outcomes Res, 2012; 12(1):23-29

  • 15. National Plan for Rare Diseases in Latvia in 2012-2015 (Nacionālais plāns reto slimību jomā Latvijā 2012.-2015.gads) // Document of working group of Ministry of Health, Riga, 2011 (Rīga. Veselības Ministrijas darba grupas dokuments, 2011) (http://phoebe.vm.gov.lv/misc_db/web.nsf/626e6035eadbb4cd85256499006b15a6/ab77e1a6c33b637dc22573d800293aaa/$FILE/reto_ricibas_plans_projkets.pdf, accessed 05.04.2013.)

  • 16. Order of reimbursement of medicines and medical devices for outpatient treatment (Ambulatorajai ārstēšanai paredzēto zāļu un medicīnisko ierīču iegādes izdevumu kompensācijas kārtība) // Regulation No. 899 of the Cabinet of Ministers, Riga, 2006 (version of 01.04.2013) (Rīga. Ministru kabineta noteikumi Nr.899, 2006) (redakcija uz 01.04.2013) (http://www.likumi.lv/doc.php?id=147522&from=off, accessed 05.04.2013.)

  • 17. Orofino J, Soto J, Casado MA, Oyagüez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007 // Appl Health Econ Health Policy, 2010; 8(5):301-315

  • 18. Pavlović N, Stanimirov B, Stojančević M, Paut- Kusturica M, Stoimenova A, Goločorbin-Kon S, Mikov M. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden // Biotechnol Biotec Eq, 2012; 26(5):3236-3241

  • 19. Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price // Appl Health Econ Health Policy, 2011; 9(4):275-279

  • 20. Register of designated orphan medicinal products // European Commission (http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm, accessed 05.04.2013.)

  • 21. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products // Official Journal of the European Communities, 2000; L18:1-5 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF, accessed 05.04.2013.)

  • 22. Reimbursement drug list, 2013 (Kompensējamo zāļu saraksts 2013) // National Health Service, Riga, 2013 (Rīga. Nacionālais veselības dienests, 2013) (http://www.vmnvd.gov.lv/lv/kompensejamiemedikamenti/kompensejamo-zalu-saraksts, accessed 05.04.2013.)

  • 23. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020 // Orphanet J Rare Dis, 2011; 6(62):1-10

  • 24. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency // Orphanet J Rare Dis, 2011; 6(42):1-8

  • 25. Spokiene I. Legal assessment of current situation on orphan patients in Lithuania // Medicina (Kaunas), 2008; 44(8):571-576

Acta Chirurgica Latviensis

The Journal of Riga Stradins University; Latvian Association of Surgeons; Latvian Association of Paediatric Surgeons

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 11 11 11
PDF Downloads 5 5 5